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ABSTRACT 
Coronary artery spasm plays an important role in the pathogenesis of many types of ischemic heart disease, not 
only in vasospastic angina but also in myocardial infarction and sudden death, particularly in the asian popula-
tion. Patients with vasospastic angina are known to have defective endothelial function due to reduced nitric oxide 
bioavailability. Moreover, markers of oxidative stress and plasma levels of C-reactive protein are elevated. Smoking, 
polymorphysms of endothelial nitric oxide synthetase (eNOS), and low-grade inflammation have been regarded 
as the most important risk factors for vasospastic angina. The recent body of evidence indicates that RhoA and 
its down stream effector, ROCK/Rho-kinase, are associated with hypercontraction of vascular smooth muscle of 
the coronary artery and regulation of eNOS activity. Thus, endothelial dysfunction through abnormalities of eNOS 
and enhanced contractility of vascular smooth muscle in coronary artery segments are considered major mecha-
nisms in vasospastic angina. However, the precise mechanisms for coronary vasospasm are not well understood. 
This article will review current understanding of the mechanism of coronary artery spasm. (Korean Circ J 2009;39: 
505-511) 
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Introduction 
 
Although prevalence of vasospastic angina appears to 
be on the decline throughout the world, probably due 
to widespread use of calcium antagonists,
1) resting chest 
pain in a relatively young patient during the early morn-
ing hours should raise the suspicion of vasospastic angina, 
particularly when occurring during sobriety. Although 
the role of coronary vasoconstriction was originally dis-
covered in “variant angina”, there is convincing evidence 
that various types of coronary constriction play a role in 
major ischemic heart disease; moreover, despite treat-
ment with calcium channel blockers and nitrate, recur-
rent episodes of angina attack in patients with vasospastic 
angina are frequently observed, whereas sudden cardiac 
death or non-fatal myocardial infarction is rare.
2) There-
fore, clarification of the exact mechanisms of coronary 
artery spasm for aid in development of novel and fun-
damental therapeutic targets is very important. 
Myocardial ischemia caused by coronary artery spasm 
can develop in both large epicardial and small distal cor-
onary arteries. Reduction in epicardial coronary artery 
diameter in response to ergonovine is usually diffuse, less 
than 30%, in patients who do not have vasospastic angi-
na.
3) This constrictor response is considered to be within 
“physiological” range. Although constrictor stimuli ca-
pable of inducing myocardial ischemia do exist in a nor-
mal coronary artery, they appear to predominantly exert 
their action on small distal vessels and secondary and 
tertiary branches, rather than on proximal epicardial seg-
ments, where spasm occurs more frequently.
4) 
Recent studies have identified a number of mecha-
nisms and precipitating factors that may play a role in 
pathogenesis of vasospastic angina (Fig. 1). These include 
endothelial dysfunction, smooth muscle hypersensitivity, 
increased autonomic tone, increased oxidative stress, de-
creased magnesium, low-grade inflammation, and ge-
netic susceptibility. Pathologic mechanisms of coronary 
vasospasm causing myocardial ischemia may be multiple, 
or may have interactions with each other. For the com-
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prehensive explanation, the authors divided mechanisms 
into two parts; the first is dysfunctional vascular endo-
thelium, and the other is enhanced vascular tone of local 
smooth muscle. In the present review, we will discuss our 
point of view, focusing on these two scenarios and recent 
insights into the pathophysiology of vasospastic angina. 
 
Dysfunctional Vascular Endothelium 
 
Vascular endothelium and nitric oxide 
The endothelium is a single-cell lining covering the 
internal surface of blood vessels, cardiac valves, and nu-
merous body cavities; it is composed of approximately 1 
to 6×10
13 cells, and covers a surface area equivalent to 
about six tennis courts.
5) Yet, as recently as the first half 
of the 20th century, endothelial cells were simply regard-
ed as barriers to blood flow. However, it was recently re-
cognized that the vascular endothelium, which is strate-
gically located to “sense” changes in hemodynamic forces 
and blood-borne signals and to “respond” by releasing a 
number of vasoactive substances, is a multifunctional or-
gan with complex metabolic capabilities, including re-
gulation of vascular tone, cellular adhesion, thrombore-
sistance, smooth muscle cell proliferation, and vessel wall 
inflammation.
5)6) Therefore, the integrity of the vascular 
endothelium and a well-balanced release of numerous 
vasoactive substances are considered essential to normal 
vascular physiology, and its dysfunction can be critical 
to pathogenesis of vascular disease.
7) 
Vascular endothelium undergoes a constant process of 
injury and repair in response to mechanical and chemi-
cal injury. At the site of tissue vascularization, endothe-
lial cells can originate either from adjacent preexisting 
blood vessels or from recruitment of bone marrow-de-
rived circulating endothelial progenitor cells (EPCs). Re-
pair with EPCs is associated with normalization of en-
dothelial function at the site of injury,
8)9) and impairment 
of the ability to participate in vascular repair has been 
demonstrated in an animal model of decreased nitric ox-
ide (NO) activity.
10) NO, synthesized from L-arginine by 
an endothelial isoform of NO synthase (eNOS), is a key 
endothelium-derived relaxing factor (EDRF), and plays 
a pivotal role in maintenance of vascular homeostasis 
(Fig. 2).
11) NO synthesis is specifically blocked by L-mo-
nomethy-arginine (L-NMMA).
12) Although NO was dis-
covered as a vasodilator, NO has multiple antiatherogenic 
roles, including an anti-inflammatory, antithrombotic, 
antiproliferative, and antioxidant effect.
13) Thus, vascular 
endothelial dysfunction may be associated with a relative 
deficiency of EPCs and/or decreased NO activity in vas-
cular repair.
14)15) 
 
Atherosclerosis and vasospastic angina 
Endothelial dysfunction, as characterized by impair-
ment of endothelium-dependent relaxation, and thereby 
reduced eNOS-derived NO bioactivity, is a critical step 
in development of atherosclerosis.
16)17) It is well known 
that atherosclerotic disease affecting large coronary ar-
Endothelial dysfunction 
Low-grade inflammation 
Oxidative stress↑ 
Genetic susceptibility 
Magnesium↓ 
Autonomic tone↑ 
Smoking 
Smooth muscle hypersensitivity 
Fig. 1. Mechanisms and precipitating factors of vasospastic angina. A number of mechanisms and precipitating factors may play a role
in pathogenesis of vasospastic angina. Endothelial nitric oxide activity is reduced and markers of low-grade inflammation and oxidative
stress are elevated in patients with vasospastic angina. Magnesium deficiency may be related to coronary vasospasm in some patients,
and smoking is regarded as an independent risk factor for development of vasospastic angina. Recently, hyper-contraction of smooth
muscle of the coronary artery in the presence of increased Ca
2+ sensitivity has been considered an important molecular mechanism of
coronary vasospasm. Pathologic mechanisms of coronary artery vasospasm causing myocardial ischemia might be multiple, or might
interact with each other.  
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teries can alter their vasomotor tone and reactivity.
18-20) 
MacAlpin
21) reported 88% localization of coronary ar-
tery spasm at the site of an atherosclerotic lesion, and 
some studies using intravascular ultrasound have reveal-
ed atherosclerotic plaques in just about any spastic seg-
ment.
22) A report using histological evaluation of coro-
nary plaques in patients with vasospastic angina also 
revealed evidence of inflammatory cell infiltration.
23) Us-
ing a porcine model of atherosclerosis with endotheli-
um removal and high-cholesterol feeding, intracoronary 
histamine or serotonin induced coronary artery spasm 
at the site of the atherosclerotic lesion, revealing a close 
topological correlation between the spastic site and the 
atherosclerotic lesion.
24)25) These results provided evi-
dence of a close relationship between coronary artery 
spasm and coronary atherosclerosis. 
Although presence of atherosclerosis may impair endo-
thelium-dependent dilation to acetylcholine (ACh), ACh 
has a major direct constrictor action on smooth muscle 
at high doses in subjects with angiographically normal 
arteries.
26) In addition, a discrepancy exists between ACh-
induced coronary spasm and spontaneous spasm or that 
induced by ergonovine or serotonin.
27)28) ACh-induced 
coronary spasm is relatively diffuse, involving all coronary 
segments, whereas spontaneous spasm or that induced 
by ergonovine or serotonin occurs at a given coronary 
segment. In addition, observation of responses to sub-
stance P, a pure endothelium-dependent vasodilator, has 
led some investigators to the conclusion that endothelial 
dysfunction does not occur in patients with vasospastic 
angina.
29)30) Therefore, because it lacks the ability to dis-
criminate the role of endothelial dysfunction from that 
of vascular smooth muscle hypersensitivity, ACh may not 
be a suitable agent for evaluation of endothelial dysfunc-
tion of coronary arteries.
26) 
 
Decreased nitric oxide activity and vasospastic   
angina 
ACh, serotonin, or histamine, all endothelium-de-
pendent vasodilators by release of NO, induce coronary 
dilation in young healthy subjects, but cause paradoxical 
vasoconstriction in patients with coronary atherosclero-
sis.
7)12)31) Therefore, endothelial function of the coronary 
arteries has been evaluated using intracoronary or intra-
venous injection of endothelial-dependent vasodilators, 
such as ACh. Coronary arteries of patients with vasospa-
stic angina are highly sensitive to the vasoconstrictor ef-
fect of intracoronary ACh injection.
32) 
In addition, nitrates, including nitroglycerin, are en-
dothelium-independent vasodilators that cause vasodi-
latation by way of their conversion to NO; the response 
of nitroglycerin is markedly increased in spasm arteries 
compared to control arteries,
33) an indication that remov-
al of basal NO-mediated vasodilatation leads to super-
sensitivity to an exogenous nitrovasodilator. Thus, defi-
ciency of both basal and ACh-induced NO activity in 
spasm arteries in patients with vasospastic angina is quite 
possible.
33-35) 
Deficiency of NO activity may be due either to a de-
crease in production or an increase in degradation of 
NO. Studies using a specific NO synthase inhibitor, L-
NMMA, have already reported endothelial dysfunction 
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Fig. 2. Endothelium-dependent relaxation of smooth muscle. Nitric oxide (NO) is synthesized in endothelial cells from L-arginine by endo-
thelial NO synthase. Following uptake into vascular smooth muscle cells, NO stimulates soluble guanylyl cyclase to form cyclic guanosine
monophosphate (cGMP). cGMP activates cGMP-dependent protein kinase, resulting in protein phosphorylation, myosin light chain depho-
sphorylation, and relaxation (Adapted and modified from reference 67). GTP: guanosine triphosphate.  
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with decreased endothelial NO production in patients 
with vasospastic angina.
33) A strong association of poly-
morphisms of T-
786C in the 5’-flanking region and Glu-
298Asp in exon7 of the eNOS gene with vasospastic an-
gina and compromised endothelial NO production has 
recently been demonstrated.
36)37) 
 
Increased oxidative stress and vasospastic angina 
Oxygen free radicals can directly damage endothe-
lial cells and degrade NO, leading to vasoconstriction.
12) 
However, direct evidence of the role of oxidative stress in 
patients with vasospastic angina is lacking. Epidemiolo-
gical studies have shown that cigarette smoking is a ma-
jor risk factor for vasospastic angina.
38) In animal models, 
cigarette smoke, which contains large amounts of oxygen 
free radicals, suppressed ACh-induced endothelium-de-
pendent vasodilatation, and this suppression was pre-
vented by antioxidants or superoxide dismutase.
39-41) Pa-
tients with vasospastic angina have low antioxidant con-
centrations, and administration of antioxidants (such as 
vitamin C and E) has been shown to improve endothe-
lium-dependent vasodilatation.
42)43) Therefore, antioxi-
dant therapy, in addition to conventional treatment, will 
be beneficial in treatment of vasospastic angina. The an-
tioxidant activity of high-density lipoprotein is known to 
protect low density lipoprotein-cholesterol (LDL) against 
oxidative modification via paraoxonase by preventing ac-
cumulation of lipid peroxides.
44) A significant associa-
tion between vasospastic angina and the paraoxonase 
gene Glu192Arg (Q182R) polymorphism was recently 
reported.
45) 
 
Imbalance between vasoconstrictor and 
vasodilator 
In addition to a decrease in production or an increase 
in degradation of NO, resulting in deficiency of NO ac-
tivity, there can be an imbalance between endothelium-
produced vasodilator factors (i.e., prostacyclin, NO) and 
vasoconstrictor factors (i.e., endothelin, angiotensin II) 
that favors the latter.
46) NO is known to suppress produc-
tion of endothelin-1 and angiotensin II, which are po-
tent vasoconstrictors and proliferators of vascular smooth 
muscle, and deficiency of NO may enhance synthesis of 
these vasoconstrictors.
47)48) Endothelium also produces 
vasodilators, such as prostacyclin
49) or hyperpolarizing 
factor,
50) and vasoconstrictors, such as endothelins
51) or 
endithelium-dependent constricting factors.
52) There-
fore, it is possible that decrease of vasodilators or increase 
of vasoconstrictors may also be involved in pathogenesis 
of vasospastic angina.   
 
Chronic low-grade inflammation and vasospastic   
angina 
Since 1978, when Lewis and co-workers first reported 
on a case connecting inflammation and vasospastic angi-
na,
53) the body of evidence suggesting a relationship bet-
ween inflammation and coronary vasospasm has grown.
54) 
Circulating plasma levels of P-selectin, E-selectin, and 
intercellular cell adhesion molecule-1 were elevated in 
patients with vasospastic angina, indicating an associa-
tion of endothelial damage and inflammatory reaction 
with coronary vasospasm.
55)56) Hung et al.
57) prospectively 
investigated the association of high-sensitivity C-reactive 
protein (CRP), a sensitive marker of inflammation, with 
coronary vasospasm and no hemodynamically significant 
coronary artery disease in a sample of 428 patients who 
underwent coronary angiography. Results showed that 
high-sensitivity CRP level was independently associated 
with a diagnosis of coronary vasos-pastic angina. These 
observations indicate that chronic low-grade inflamma-
tion plays an important role in pathogenesis of coronary 
vasospasm. However, much more research regarding the 
direct association between inflammation and vasospastic 
angina is obviously needed. 
 
Controversies Regarding 
Dysfunctional Endothelium Versus 
Enhanced Smooth Muscle Contractility 
 
Shimokawa
58) reasoned that coronary artery spasm is 
caused primarily by hypercontraction of coronary smooth 
muscle cells, although endothelial dysfunction may be 
important in induction of early atherosclerotic changes 
of the coronary artery, favoring occurrence of a spasm. 
Reasons for this notion are as follows: First, coronary ar-
tery spasm occurs at a given site within the atherosclerotic 
coronary artery, whereas endothelial dysfunction appears 
to be more generalized throughout the epicardial coro-
nary arteries or in blood vessels throughout the body. 
Second, vasodilating responses to bradykinin or sub-
stance P, both of which are endothelium-dependent va-
sodilators, are fairly well preserved at the spastic coronary 
segment in patients with vasospastic angina. Third, the 
coronary atherosclerotic lesion remains at the spastic site, 
even after spontaneous remission of the spastic activity 
of the coronary artery in patients with vasospastic an-
gina. Forth, although long-term treatment with fish oils 
is known to improve endothelial vasodilator function, 
vasospastic activity in patients with vasospastic angina can 
last even longer after long-term treatment with eicosa-
pentaenoic acid, a major component of fish oils respon-
sible for augmentation of endothelial function. Fifth, if 
endothelial dysfunction plays a primary role in patho-
genesis of coronary vasospasm, then the prevalence and 
severity of endothelial dysfunction in the coronary artery 
would be greater and more frequent in Asian patients 
with vasospastic angina than in their Caucasian counter-
parts; however, this may not be the case. Finally, contrac-
tility of coronary smooth muscle cells is indeed augment-
ed at the spastic coronary segment in a patient with  
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vasospastic angina and in porcine models of coronary 
artery spasm.   
 
Enhanced Vascular Smooth 
Muscle Contractility 
 
Vascular smooth muscle contraction and relaxation 
are regulated by phosphorylation and dephosphoryla-
tion of myosin light chain by myosin light chain kinase 
(MLCK) and myosin light chain phosphatase (MLCP).
59) 
Vascular smooth muscle contraction is initiated by bind-
ing of various agonists or stimuli, such as serotonin or 
histamine, to their receptors; phospholipase C is activat-
ed, leading to formation of inositol 1,4,5-triphosphate 
(IP3) and diacylglycerol (DAG). IP3 then binds to its re-
ceptor on the membrane of the sarcoplasmic reticulum 
(SR) to mobilize stored calcium irons (Ca
2+) into the cy-
tosol. The Ca
2+/calmodulin complex then activates ML-
CK, with subsequent phosphorylation of myosin light 
chain.
60) Thus, the more intracellular Ca
2+ concentration 
is increased, the more contraction of vascular smooth 
muscle will occur. This is known as a classical pathway for 
vascular smooth muscle contraction. 
However, it is also well known that the relationship 
between elevation of cytosolic Ca
2+ concentration and 
the degree of developed tension varies depending on the 
situation.
61) The Ca
2+-tension relationship changes dur-
ing the time course of the contraction, in which the sus-
tained phase of the contraction is maintained by a rela-
tively lower level of cytosolic Ca
2+. This phenomenon is 
referred to as “Ca
2+” sensitization of the contractile appa-
ratus” or “an increase in Ca
2+ sensitivity”.
59) Therefore, 
contraction of vascular smooth muscle is subjected to 
dual regulation by the Ca
2+-dependent and the so-called 
Ca
2+ independent signal. Ca
2+ sensitivity can be regu-
lated by either myosin light chain phosphorylation-de-
pendent or -independent mechanisms, while phosphory-
lation-dependent mechanisms are considered to play a 
major role in regulation of Ca
2+ sensitivity.
62) However, 
investigation of the molecular mechanisms of enhanced 
smooth muscle responsiveness in patient with vasospastic 
angina is not easy, due to the difficulty of obtaining tis-
sue specimens of human coronary spastic segments. 
Recent evidence indicates that small GTPase RhoA 
and its downstream effector, ROCK/Rho-kinase, inhibits 
MLCP, leading to augmentation of myosin light chain 
phosphorylation and Ca
2+ sensitization in response to 
vasoconstrictor stimuli (Fig. 3). In order to elucidate the 
molecular mechanism of coronary artery spasm, Shimo-
kawa and colleagues
58) have developed porcine models of 
coronary artery spasm by chronic application of interleu-
kin-β   (IL-β) to the coronary artery of porcine and by re-
Receptor
PKC 
RhoA 
MBS 
MLCPh 
Myosin Myosin Actin 
MBS
MLCPh
Rho-kinase 
MLCK
Contraction 
DAG  IP3
Ca2+
CaM
L-type 
Ca channel
ATP  ADP
Fasudil 
Y-27632 
CPI 17 MLCPh inhibitor
- 
-
P 
P
P
P
ATP ADP
Ca2+
PLC
Fig. 3. Molecular mechanisms of coronary artery spasm. Upon stimulation by various agonists, the Rho/Rho-kinase-mediated pathway is
activated, resulting in inhibition of myosin phosphatase (via phosphorylation of its myosin binding subunit), with a resultant increase in my-
osin light-chain phosphorylation and vascular smooth muscle hypercontraction. By contrast, the contribution of intracellular Ca
2+ release
may be minimal. With regard to the Rho/Rho-kinase-mediated pathway, several alterations could be involved, including enhanced ex-
pression of Rho/Rho-kinase, increased Rho-kinase activity, and inhibition of myosin phosphatase activity, all of which could eventually
enhance myosin light-chain phosphorylation. PLC: phospholipase C, DAG: diacylglycerol, PKC: protein kinase C, IP3: inositol-1,4,5-tri-
phosphate, CaM: calmodulin, MLC: myosin light chain, MBS: myosin binding subunit, MLCK: myosin light-chain kinase (Adapted and
modified from reference 68). 
Hypercontraction  
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moval of the endothelium with high-cholesterol feed-
ing. Significantly increased and upregulated expression 
of ROCK/Rhokinase messenger RNA (mRNA) at the 
spastic rather than the control segment was demonstrat-
ed in this porcine model. They also showed that Fasudil, 
a specific inhibitor of ROCK/Rhokinase, inhibited cor-
onary artery spasms in animals
63) and humans.
64) These 
results indicate that ROCK/Rhokinase plays a key role 
in induction of vascular smooth muscle hypercontrac-
tion by inhibition of MLCP through phosphorylation 
of myosin binding subunit.
59) The exact mechanisms by 
which the activity of ROCK/Rho-kinase is increased re-
main to be elucidated.   
Recent studies have shown that eNOS is regulated by 
the ROCK/Rho-kinase pathway. Inhibition of RhoA 
geranylgeranylation by statins decreases membrane GTP-
bound active RhoA and subsequent ROCK activity, lead-
ing to upregulation and activation of eNOS;65) further-
more, direct inhibition of the ROCK/Rho-kinase path-
way has been shown to increase eNOS expression.
66) Thus, 
ROCK/Rho-kinase is closely associated with endothelial 
NO activity. 
 
Conclusion  
 
Although coronary artery spasm plays an important 
role in pathogenesis of many types of ischemic heart dis-
ease, the cellular and molecular mechanisms of the spasm 
are still not well understood. It is possible that patients 
with vasospastic angina might have a disturbance in en-
dothelial function, as well as an enhanced response of 
the vascular smooth muscle of the coronary artery and 
some final common molecular mechanisms. Further stu-
dies are required for clarification of the molecular and 
cellular mechanisms of this little-known disease of the 
coronary artery. 
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